MedTech-related health technology assessments from NIHR in October 2022 In October 2022, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related report in its Health Technology Assessment (HTA) Journal, which concerned photodynamic versus white-light-guided resection of non-muscle-invasive bladder cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in October 2022. Fourteen recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular, neurovascular, orthopedic, and ENT devices, as well as medical aids.

On October 31, 2022, the Dental and Pharmaceutical Benefits Agency (TLV) initiated conducting a theme survey for technologies used for the diagnosis or treatment of lung or colorectal cancer. Manufacturers of medical devices have an opportunity to notify TLV about a new product related to the theme of the survey. The notification form is available on the TLV website and should be submitted no later than November 22, 2022.

In October 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (YAG laser vitreolysis for symptomatic vitreous floaters, transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine), one Medical Technologies Guidance (Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer) and three new Medtech Innovation Briefings (O2matic PRO 100, Daylight, Signatera). Also, one new clinical guideline was published on osteoarthritis.

In October 2022, the Norwegian Directorate of Health published a preliminary version of the DRG system (Innsatsstyrt finansiering, ISF) for 2023. Eight new DRGs will be added in 2023.

On October 19, 2022, it was announced by the Ministry of Health that the 2023 General State Budget in the field of health would comprise €2,746.17 million, which is €199.32 million (7.83%) more than in 2022. The aim is to strengthen the National Health System (SNS) and achieve a more robust, more equitable, and more modern system capable of adapting to the population's health needs.

On October 17, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decision, recommending the transfer to standard care for another completed project. The project relates to the improvement of the management of cancer patients.

In October 2022, Ordering Forum for New Methods framework in Norway invited interested parties regarding hand-held electrocardiogram (ECG) devices connected to an app for diagnosing atrial fibrillation in adults (e.g., KardiaMobile). Information shall be submitted no later than November 29, 2022. Ordering Forum will be held on December 12, 2022, to decide whether the method will undergo evaluation at the national level.

In the second half of October 2022, 47 new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL). These codes became valid on November 1, 2022. The introduced codes are dedicated to diagnostic imaging, endoscopy, gastrointestinal, radiotherapy, pulmonary and airways, surgical procedures, and some other fields.

On October 12, 2022, the National Institute for Health and Care Excellence (NICE) announced the launch of an official collaboration with five other HTA bodies from Canada, Australia, Scotland, and Wales. The partners will remain independent and work together on shared priorities. Five initial priority areas have been agreed upon, including COVID-19, digital health, and Artificial Intelligence. The partnership could be expanded to include other HTA bodies in the future.

The “New Method” is currently developing criteria for which methods other than drugs shall be prioritized for assessment within the framework at the national or local levels. On October 04, 2022, the development status was reported to the Ministry of Health and Care with the proposal on how the existing criteria could be used together with the criteria of the regulatory work in HTA.

In late September – early October 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by sickness funds.